Four monoclonal antibodies have been approved for migraine prevention (erenumab, eptinezumab, fremanezumab, galcanezumab) [15,30], the first of them targeting the CGRP-R and the three others targeting the CGRP ligand. Here, CALCA is linked to migraine disorder.